Since establishment, we have been playing a lead role in offering Myhep Ledipasvir and Sofosbuvir Tablets. These tablets are used for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. Our diligent agents` source these tablets from the most authentic vendors of the market. The recommended dosages of Myhep Ledipasvir and SofosbuvirTablets is one tablet taken orally once daily with or without food. We offer these tablets at cost-effective prices to clients.
Myhep Lvir Tablets Features:
- Safe to consume
- Oral administration
- Extended shelf life
Myhep Lvir Tablets Price in India
MyHep LVIR is a fixed-dose combination tablet containing ledipasvir and sofosbuvir for oral administration.Each film, coated tablet contains 90 mg ledipasvir and 400 mg sofosbuvir.
INDICATIONS AND USAGE
MyHep LVIR is indicated for the treatment of choronic hepatitis C (CHC) genotype 1 infection in adults.
Myhep Lvir DOSAGES
Myhep Lvir Recommended Dosage in Adults
MyHep LVIR is two-drug fixed-dose combination product that contained 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet. The recommended dosages of MyHep LVIR is one tablet taken orally once daily with or without food.
Duration of treatment
Relapse rates are affected by baseline host and viral factors and differences between treatment durations for certain subgroups. Below provides the recommended Myhep Lvir treatment durations for treatment-naive and treatment-experienced patients and those with and without cirrhosis.
- MyHep LVIR for 8 weeks can be considered in treatment-naÃ¯ve patients without cirrhosis who have pre-treatment HCV RNA less than 6 million IU/ mL .
- Treatment-experienced patients who have failed treatment with either peginterferon alfa ribavirin or an HCV protease inhibitor peginterferon alfa ribavirin
Myhep Lvir DOSAGES FORMS AND STERENGTHS
MyHep LVIR is available as Green colored, oval shaped, film coated tablet debossed with on one side and plain on other side of the tablet.Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir.
No contraindications have been identified.
WARNINGS AND PRECAUTIONS
Serious Symptomatic Bradycardia When Coadministered with Amiodarone
Postmarketing cases of symptomatic bradycardia, as well as fetal cardiac arrest and cases requiring pacemaker intervention, have been reported when amiodarone is coadministered with Ledipasvir Sofosbuvir.Bradycardia has generally occurred within hours to days,btus cases have been observed up to 2 weeks after initiating HCV treatment.Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone.Bradycardia generally resolved after discontinuation of HCV treatment.The mechanism for this effect is unknown.
Clinical Trials Experience
The most common adverse reactions (>=10%) were fatigue and headache Nausea, Diarrhea, Insomnia in subjects treated with 8, 12, or 24 weeks of Ledipasvir Sofodbuvir.